NPRL2 gene therapy induces robust antitumor immunity and overcome anti-PD1 resistance through augmenting antigen-presentation and cytotoxic T cells activation in KRAS/STK11 mutant NSCLC in humanized mouse model.
Oversized mammalian cells reduce their growth efficiency by activating global protein degradation, which functions in parallel with the cell size checkpoints, to promote cell size homeostasis.